Stock NVCT NUVECTIS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Nuvectis Pharma, Inc.

Equities

NVCT

US67080T1088

Real-time Estimate Cboe BZX
Other stock markets
 09:18:33 26/06/2024 pm IST 		5-day change 1st Jan Change
7.335 USD +3.31% Intraday chart for Nuvectis Pharma, Inc. +7.69% -11.81%
07/05 Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
08/04 Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines CI

Evolution of the average Target Price on Nuvectis Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

733386ad51e8c6ce01.0cfBR0eHaeGGmfLA2dJwI5gSD8mNmr1-y7zE9C8pf0k.loaoAR7WUYLh2KP57ZFJGs0qa7788-oOhP3pwVpZFACZoLEzNPQFscD9xg~05b14e228d3cfe88eccf1d53bd4dabac

Analyst Recommendations on Nuvectis Pharma, Inc.

Ladenburg Thalmann Initiates Nuvectis Pharma at Buy with $21 Price Target MT
HC Wainwright Initiates Nuvectis Pharma at Buy With $14 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.1 USD
Average target price
22 USD
Spread / Average Target
+209.86%
High Price Target
25 USD
Spread / Highest target
+252.11%
Low Price Target
20 USD
Spread / Lowest Target
+181.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nuvectis Pharma, Inc.

Ladenburg Thalmann
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NVCT Stock
  4. Consensus Nuvectis Pharma, Inc.